PUBLISHER: IMARC | PRODUCT CODE: 1541719
PUBLISHER: IMARC | PRODUCT CODE: 1541719
The global antifungal drugs market size reached US$ 15.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2032, exhibiting a growth rate (CAGR) of 3.1% during 2024-2032.
Antifungal drugs, or antimycotic drugs, refer to the pharmaceutical medicines used for the treatment of fungal infections on skin, hair and nails. Some of the commonly used antifungal drugs include polyenes, azoles and allylamines. They specifically neutralize fungal agents and dermatophytes, such as candida and tapeworms, and aid in the treatment of athlete's foot, ringworm, aspergillosis, candidiasis and fungal meningitis. These drugs are commonly available in over the counter (OTC) capsule, gel, liquid and pill variants or intravenous solutions that are injected directly into the bloodstream to minimize and prevent fungal infection.
The increasing prevalence of fungal and nosocomial infections is one of the key factors creating a positive outlook for the market growth. Antifungal drugs are effective against both systemic and superficial infections that are acquired from exposure to contaminated surfaces in hospitals or humid conditions. Moreover, the convenient availability of OTC drugs in both urban and rural areas is providing a thrust to the market growth. With the rising health consciousness among the masses, consumers are increasingly opting for OTC therapeutics to timely treat minor infections. Additionally, various product innovations, such as the development of synthetic and semi-synthetic azole-based compounds for the treatment of invasive fungal infections, are acting as other growth-inducing factors. Pharmaceutical manufacturers are also investing extensively in the research and development (R&D) of novel therapeutics in the form of sprays, creams, tablets and injections with enhanced efficacy. Other factors, including significant growth in the pharmaceutical industry, along with the implementation of favorable government policies promoting public health, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global antifungal drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class and indication.
Azoles
Voriconazole (Vfend)
Posaconazole (Noxafil)
Clotrimazole (Canesten)
Isavuconazole (CRESEMBA)
Others
Echinocandins
Caspofungin (Cancidas)
Micafungin (Mycamine/ Funguard)
Others
Polyenes
Amphotericin (AmBisome)
Others
Allylamines
Terbinafine (Lamisil)
Others
Others
Dermatophytosis
Aspergillosis
Candidiasis
Invasive Candidiasis
Vulvovaginal Candidiasis (VVC)
Mouth/Throat/Esophageal Candidiasis
Others
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arcadia Consumer Healthcare Inc., Astellas Pharma Inc., Bayer AG, GlaxoSmithKline Plc, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Scynexis Inc.